Anticoagulant therapies and outcomes in obese patients with acute venous thromboembolism
- 1 March 2020
- journal article
- research article
- Published by Elsevier BV in Thrombosis Research
- Vol. 187, 56-62
- https://doi.org/10.1016/j.thromres.2020.01.011
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled AnalysisCirculation, 2014
- Edoxaban versus Warfarin for the Treatment of Symptomatic Venous ThromboembolismThe New England Journal of Medicine, 2013
- Oral Apixaban for the Treatment of Acute Venous ThromboembolismThe New England Journal of Medicine, 2013
- Direct anticoagulant drugs to overcome limitations of vitamin K antagonists. A critical appraisal of data in atrial fibrillation patientsEmerging Drugs, 2013
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismThe New England Journal of Medicine, 2012
- Association Between Medication Possession Ratio, Virologic Failure and Drug Resistance in HIV-1–Infected Adults on Antiretroviral Therapy in Côte d'IvoireJAIDS Journal of Acquired Immune Deficiency Syndromes, 2011
- Oral Rivaroxaban for Symptomatic Venous ThromboembolismThe New England Journal of Medicine, 2010
- Accuracy of coding for possible warfarin complications in hospital discharge abstractsThrombosis Research, 2006
- Obesity as a risk factor in venous thromboembolismAmerican Journal Of Medicine, 2005
- Natural History of Venous ThromboembolismCirculation, 2003